RTP Mobile Logo

Armitage JO, Longo DL. Which anti-CD20 antibody is better in follicular lymphoma? N Engl J Med 2017;377(14):1389-90. Abstract

Bartlett NL et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial. Blood 2018;131(2):182-90. Abstract

Cheah CY, Fowler NH. Novel agents for relapsed and refractory follicular lymphoma. Best Pract Res Clin Haematol 2018;31(1):41-8. Abstract

Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018;36(22):2259-66. Abstract

Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017;35(35):3898-905. Abstract

Fowler NH et al. Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). Proc ASCO 2018;Abstract 7549.

Fowler NH et al. A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE). Proc ASCO 2017;Abstract TPS7576.

Fowler NH et al. Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study. Proc ASCO 2017;Abstract 7531.

Gopal AK et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study. J Clin Oncol 2018;36(23):2405-12. Abstract

Gopal AK et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 2017;129(22):3037-9. Abstract

Hiddemann W et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol 2018;36(23):2395-404. Abstract

Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int J Hematol 2016;104(3):293-9. Abstract

Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract

Morschhauser F et al. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood 2018;132(14):1486-94. Abstract

Morschhauser F et al; RELEVANCE trial investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934-47. Abstract

Nastoupil L et al. High complete response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Results of an open-label, phase II study. Proc ASH 2017;Abstract 414.

Schuster SJ et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017;377(26):2545-54. Abstract

Sehn LH et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. Proc ASCO 2018;Abstract 7507.

Smith SM et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol 2017;4(4):e176-82. Abstract

Strati P et al. Long-term remissions of patients with follicular lymphoma grade 3 treated with R-CHOP. Clin Lymphoma Myeloma Leuk 2018;18(1):e103-8. Abstract

Tilly H et al; Lymphoma Study Association. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: A single-arm, open-label, phase 2 study. Lancet Haematol 2018;5(9):e403-10. Abstract

Tran E et al. A milestone for CAR T cells. N Engl J Med 2017;377(26):2593-6. Abstract

Younes A et al. Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: An interim analysis. Proc ASH 2017;Abstract 481.